BridgeBio Pharma, Inc. (BBIO) Stock

BridgeBio Pharma, Inc. (BBIO) is a Healthcare stock trading at $81.08 (as of 2026-08-24), with a market capitalization of $15.85B. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Understand BridgeBio Pharma, Inc.: how it makes money

BridgeBio develops small-molecule drugs for rare genetic diseases and sells approved products to patients at high per-prescription prices. With roughly 30 pipeline programs against one or two approved drugs, it is a pre-profit orphan franchise where clinical readouts matter more than current cash flow.

High-priced orphan drugs generate 94% gross margins, but funding roughly 30 simultaneous R&D programs absorbs every dollar of that gross profit, so clinical approval milestones are the actual profit engine until the pipeline narrows.

Business quality (Weak): Pre-profit biotech: 94% gross margin confirms real drug economics, but -44% operating margin and -661% ROE show the company is still deeply in the spend-down phase of a large pipeline. Grade: Weak on current financials, though the 120% revenue growth signals a turning point if products continue to scale.

Bull case

Orphan drug scaling rapidly: Quarterly revenue reached $200M, up 120% year over year as the approved product ramps through specialist and cardiologist channels. At that growth rate from a $200M/quarter base, the product is still early in its addressable-market penetration.
Phase 3 data looks strong: The lead ATTR-CM candidate (AG10/BBP-265) reported a 42% composite reduction in all-cause mortality and recurrent cardiovascular-related hospitalization events at Month 30. If it clears the finish line, it becomes a second major revenue driver in the same rare-disease franchise.

Bear case

Still burning cash at scale: Operating margin sits at -44% on $200M of quarterly drug revenue, meaning the company loses nearly half of every top line to R&D and overhead across its ~30-program pipeline. Sustainable profitability is still years away, not months.
Lower-cost alternatives eroding share: Estimated non-brand prescription share for Attruby is already 25% since FDA approval. In a narrow orphan indication where total patient counts are in the low thousands, each patient who shifts to a cheaper alternative is a meaningful, hard-to-recover revenue loss.

Valuation — source: SEC EDGAR (first-party)
Price	$81.08
Market Cap	$15.85B
Price / Sales	22.23
FCF Yield	-2.7%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$502.08M
Net Margin	-146.0%
Revenue Growth (YoY)	120.4%
EPS Growth (YoY)	-17.9%
FCF Growth (YoY)	-12.0%

Financial Health — source: SEC EDGAR
Altman Z-Score	-3.24 (distress)
Piotroski F-Score	2/9 (weak)

Valuation vs Sector & Industry
Sector P/E (Healthcare)	21.7
Industry P/E (Pharmaceutical Products)	17.1

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	VANGUARD GROUP INC ($1.29B)
Institutional Holders Tracked	10
Congressional Trades (recent)	6

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Neil Kumar
Employees	725
Country	US
IPO Date	2019-06-27

Related Companies (Pharmaceutical Products; 8 comparable drugmakers)

Data as of 2026-08-24.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.